{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T03:07:49Z","timestamp":1648696069529},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.mehy.2013.09.024","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T17:02:31Z","timestamp":1380301351000},"page":"1029-1030","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic corticosteroid treatment in Peyronie\u2019s disease"],"prefix":"10.1016","volume":"81","author":[{"given":"Hakk\u0131","family":"Uzun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.mehy.2013.09.024_b0005","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1743-6109.2007.00692.x","article-title":"A brief historical survey of \u201cPeyronie\u2019s disease\u201d","volume":"5","author":"Musitelli","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2013.09.024_b0010","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1743-6109.2008.01081.x","article-title":"Peyronie\u2019s disease intervention trials: methodological challenges and issues","volume":"6","author":"Muller","year":"2009","journal-title":"J Sex Med"},{"issue":"1","key":"10.1016\/j.mehy.2013.09.024_b0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/187152812798889321","article-title":"Inflammatory mechanisms and oxidative stress in Peyronie\u2019s disease: therapeutic rationale and related emerging treatment strategies","volume":"11","author":"Paulis","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"1","key":"10.1016\/j.mehy.2013.09.024_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijir.2011.45","article-title":"Review of non-surgical treatment options for Peyronie\u2019s disease","volume":"24","author":"Larsen","year":"2012","journal-title":"Int J Impot Res"},{"issue":"1","key":"10.1016\/j.mehy.2013.09.024_b0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-5347(17)62993-8","article-title":"Steroid injection therapy for Peyronie\u2019s disease: a 10-year summary and review of 38 cases","volume":"97","author":"Desanctis","year":"1967","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.mehy.2013.09.024_b0030","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-5347(17)67169-6","article-title":"Peyronie\u2019s disease: results with dermo-jet injection of dexamethasone","volume":"114","author":"Winter","year":"1975","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.mehy.2013.09.024_b0035","first-page":"165","article-title":"Betamethasone versus placebo in Peyronie\u2019s disease","volume":"70","author":"Cipollone","year":"1998","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.mehy.2013.09.024_b0120","series-title":"Campbell\u2013Walsh Urology","author":"Wein","year":"2012"},{"key":"10.1016\/j.mehy.2013.09.024_b0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","article-title":"Proposal: trauma as the cause of the Peyronie\u2019s lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.mehy.2013.09.024_b0050","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0022-5347(01)64222-8","article-title":"Penile trauma: an etiologic factor in Peyronie\u2019s disease and erectile dysfunction","volume":"158","author":"Jarow","year":"1997","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.mehy.2013.09.024_b0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ncpuro0201","article-title":"Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie\u2019s disease","volume":"2","author":"Gonzalez-Cadavid","year":"2005","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.mehy.2013.09.024_b0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0022-5347(05)64677-0","article-title":"Steroid therapy for idiopathic retroperiteonal fibrosis: Dose and Duration","volume":"168","author":"Kardar","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2013.09.024_b0065","first-page":"w13650","article-title":"Endogenous glucocorticoids in inflammation: contributions of systemic and local responses","volume":"142","author":"Hardy","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.mehy.2013.09.024_b0070","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-5347(05)64578-8","article-title":"A retrospective review of 307 men with Peyronie\u2019s disease","volume":"168","author":"Kadioglu","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2013.09.024_b0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000475172","article-title":"Penile ossification and acquired penile deviation","volume":"27","author":"Vahlensieck","year":"1995","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.mehy.2013.09.024_b0080","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","article-title":"The management of Peyronie\u2019s disease: evidence based 2010 guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J Sex Med"},{"key":"10.1016\/j.mehy.2013.09.024_b0085","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0022-5347(01)65360-6","article-title":"The microscopic pathology of Peyronie\u2019s disease","volume":"157","author":"Davis","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.mehy.2013.09.024_b0090","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0022-5347(01)65359-X","article-title":"The anatomy of the tunica albuginea in the normal penis and Peyronie\u2019s disease","volume":"157","author":"Brock","year":"1997","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.mehy.2013.09.024_b0095","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0090-4295(01)01578-3","article-title":"Gene expression profiles in the Peyronie\u2019s disease plaque","volume":"59","author":"Magee","year":"2002","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.mehy.2013.09.024_b0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","article-title":"Anti-inflammatory actions of glucocorticoids: molecular mechanisms","volume":"94","author":"Barnes","year":"1998","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.mehy.2013.09.024_b0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2174\/187152812798889321","article-title":"Inflammatory mechanisms and oxidative stress in Peyronie\u2019s disease: therapeutic \u201crationale\u201d and related emerging treatment strategies","volume":"11","author":"Paulis","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.mehy.2013.09.024_b0110","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0165-6147(93)90184-L","article-title":"Anti-inflammatory actions of steroids: molecular mechanisms","volume":"4","author":"Barnes","year":"1993","journal-title":"Trends Pharmacol Sci"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987713004623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987713004623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T08:03:20Z","timestamp":1564128200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987713004623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0306987713004623"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2013.09.024","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic corticosteroid treatment in Peyronie\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2013.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}